Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease.
- Published In:
- European journal of clinical investigation, 55(1), e14330 (2025)
- Authors:
- Kanbay, Mehmet, Copur, Sidar, Guldan, Mustafa, Ozbek, Lasin, Mallamaci, Francesca, Zoccali, Carmine
- Database ID:
- RPEP-11703
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11703APA
Kanbay, Mehmet; Copur, Sidar; Guldan, Mustafa; Ozbek, Lasin; Mallamaci, Francesca; Zoccali, Carmine. (2025). Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease.. European journal of clinical investigation, 55(1), e14330. https://doi.org/10.1111/eci.14330
MLA
Kanbay, Mehmet, et al. "Glucagon and glucagon-like peptide-1 dual agonist therapy: A possible future towards fatty kidney disease.." European journal of clinical investigation, 2025. https://doi.org/10.1111/eci.14330
RethinkPeptides
RethinkPeptides Research Database. "Glucagon and glucagon-like peptide-1 dual agonist therapy: A..." RPEP-11703. Retrieved from https://rethinkpeptides.com/research/kanbay-2025-glucagon-and-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.